Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
A submission for 4mg and 8mg tablets of the melatonin MT1 and MT2 receptor agonist had been made under the...